Estrella Immunopharma, Inc. (ESLA)
| Market Cap | 50.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.49M |
| Shares Out | 35.20M |
| EPS (ttm) | -2.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,047 |
| Open | 1.30 |
| Previous Close | 1.31 |
| Day's Range | 1.02 - 1.36 |
| 52-Week Range | 1.02 - 33.00 |
| Beta | -0.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 19, 2023 |
About ESLA
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Est... [Read more]
Financial Performance
Financial StatementsNews
TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination
Estrella to Begin Trading on NASDAQ Under the Ticker Symbols "ESLA" and "ESLAW" Beginning October 2, 2023 NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Estrella Immunopharma, Inc., formerly known as Trade...
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
NEW YORK , Sept. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its...
Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company focusing on cancer therapeutics, and TradeUP Acquisition Corp. ("TradeUP") (...